<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551497</url>
  </required_header>
  <id_info>
    <org_study_id>1014802/102</org_study_id>
    <secondary_id>2015-001926-41</secondary_id>
    <nct_id>NCT02551497</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects</brief_title>
  <official_title>Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, placebo-controlled 3 period study to evaluate the&#xD;
      interaction between a drug and CNV1014802 in healthy male and female subjects. It is planned&#xD;
      to enrol 36 subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been&#xD;
      acquired by Biogen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2015</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 16, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-tau) of CNV1014802 and a drug</measure>
    <time_frame>days 1-28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CNV1014802 and a drug</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of AEs</measure>
    <time_frame>Days 16 to 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>Days16-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Days16-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Days 16-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>safety laboratory tests</measure>
    <time_frame>Days 16-21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNV1014802 Tmax</measure>
    <time_frame>days 1-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNV1014802 Ctrough</measure>
    <time_frame>days 1-28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Other drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other drug BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to match BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNV1014802</intervention_name>
    <arm_group_label>Other drug</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males, or non-pregnant, non-lactating healthy females either of non-child&#xD;
             bearing potential, or taking an approved method of contraception for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Age 18 to 55 years of age, inclusive&#xD;
&#xD;
          -  Non-smoking subjects with body weight ≥45 kg&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to 32 kg/m2 (inclusive)&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          -  Must provide written informed consent&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical research study within the previous 3 months&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study (male subjects &gt;21&#xD;
             units per week or female subjects &gt;14 units per week; 1 unit = ½ pint beer, 25 mL of&#xD;
             40% spirit or a 125 mL glass of wine)&#xD;
&#xD;
          -  Positive alcohol breath test&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 6 months. A breath carbon&#xD;
             monoxide reading of greater than 10 ppm at screening&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant or lactating (female subjects must&#xD;
             have a negative urine pregnancy test at admission)&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator at screening&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, haematology or urinalysis&#xD;
&#xD;
          -  Positive drugs of abuse test result&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
          -  Positive genotyping test&#xD;
&#xD;
          -  History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal&#xD;
             disease as judged by the investigator&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hayfever is allowed unless it is active&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period&#xD;
&#xD;
          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than hormone replacement therapy [HRT]/hormonal contraception not containing ethinyl&#xD;
             estradiol) or herbal remedies in the 14 days before IMP administration&#xD;
&#xD;
          -  Significant medical history of fainting or vasovagal attacks&#xD;
&#xD;
          -  History of uncontrolled or poorly controlled hypertension&#xD;
&#xD;
          -  Semi-supine systolic BP &lt;90 mmHg or &gt;140 mmHg, or diastolic BP &gt;100 mmHg after 3&#xD;
             assessments&#xD;
&#xD;
          -  QTcB or QTcF of &gt;450 msec in male subjects or &gt;470 msec in females&#xD;
&#xD;
          -  Presence or history of any clinically significant abnormality in vital signs or ECG&#xD;
&#xD;
          -  Presence of any medical condition, which in the opinion of the investigator may&#xD;
             interfere with the study procedures or compromise subject safety&#xD;
&#xD;
          -  Medical history of clinically significant depression&#xD;
&#xD;
          -  History of suicide attempt within 6 months prior to screening&#xD;
&#xD;
          -  History of acute porphyria&#xD;
&#xD;
          -  History of cardiac conduction disorders with the exception of 1st degree heart block&#xD;
&#xD;
          -  Mentally or legally incapacitated&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol, or to&#xD;
             comply with study restrictions on smoking, concomitant medications and diet&#xD;
&#xD;
          -  Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteer drug interaction study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

